Meet Ubiquigent at the upcoming SCI meeting on the 14th September, Hatfield, UK- Innovation in design, supply and acquisition for compound screening libraries
Dr John Harris CChem FRSC, Member of Scientific Advisory Board, Ubiquigent Ltd will be giving a short presentation – Targeted chemical libraries: the keys to unlock the ubiquitin system.
The widespread use of target-focused libraries as a key research tool in drug discovery has led to success against many classes of drug target, but the ubiquitin system still remains a largely untapped medicinal chemistry opportunity awaiting well-designed and broadly applicable tools of this type. Protein kinases, on the other hand, have become one of the most important classes of drug targets for the pharmaceutical industry and the clinic over the last decade, driven substantially by the exploitation of kinase-focused libraries. As with protein phosphorylation by kinases, protein ubiquitylation regulates many aspects of cell function and provides a wealth of drug target opportunities across many therapeutic areas including cancer, cardiovascular and metabolic disease, inflammation, neurodegeneration and infectious diseases.
This presentation will provide an overview of how we are addressing the opening up of the ubiquitin system for drug discovery through a focused library collaboration between Ubiquigent and the Drug Discovery Unit at the University of Dundee which has led to the development of the first commercially available compound library designed specifically to target deubiquitylase (DUB) enzymes, DUBtarget™-001.